Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 14, 2011; 17(6): 804-808
Published online Feb 14, 2011. doi: 10.3748/wjg.v17.i6.804
Published online Feb 14, 2011. doi: 10.3748/wjg.v17.i6.804
Table 1 Baseline characteristics of patients included in this study n (%)
Characteristic | Study group | Control group | P |
No. of patients | 332 (100) | 966 (100) | |
Gender | NS | ||
Male | 196 (59.0) | 550 (55.0) | |
Female | 136 (41.0) | 416 (45.0) | |
Age (yr) | NS | ||
Median | 53 | 60 | |
Range | 16-81 | 16-87 | |
Depth of tumor invasion1 | 299 (100) | 857 (100) | NS |
T1 | 21 (6.3) | 40 (4.1) | |
T2 | 38 (11.4) | 165 (17.1) | |
T3 | 87 (26.2) | 264 (27.3) | |
T4 | 153 (46.1) | 388 (40.2) | |
Lymph-node metastasis1 | 295 (100) | 843 (100) | NS |
N0 | 160 (48.2) | 490 (58.1) | |
N1 | 87 (26.2) | 216 (25.6) | |
N2 | 48 (14.5) | 137 (14.2) | |
Chronic liver dysfunction2 | 39 (11.7) | 65 (6.7) | < 0.05 |
Albumin (g/dL) | 39.4 ± 5.5 | 39.4 ± 11.1 | NS |
Total bilirubin (mg/dL) | 13.0 ± 5.8 | 12.7 ± 6.7 | NS |
LDH (IU/L) | 191.5 ± 141.7 | 197.5 ± 164.1 | NS |
ALP (IU/L) | 71.7 ± 35.5 | 75.6 ± 49.7 | NS |
GGT (IU/L) | 34.7 ± 54.9 | 35.4 ± 55.9 | NS |
Table 2 Synchronous and metachronous metastasis in two groups n (%)
Sites of metastasis | Study group (n = 332) | Control group (n = 966) | P value | HR (95% CI) |
Liver | < 0.01 | 0.50 (0.38-0.66) | ||
Yes | 47 (14.2) | 272 (28.2) | ||
No | 285 (85.8) | 694 (71.8) | ||
Extrahepatic | < 0.01 | 1.88 (1.52-2.33) | ||
Yes | 106 (31.9) | 164 (17.0) | ||
No | 226 (68.1) | 802 (83.0) |
Table 3 Synchronous and metachronous metastasis in chronic hepatitis B and control groups n (%)
Metastatic sites | CHB group (n = 37) | Control group (n = 966) | P value | HR (95% CI) |
Liver | < 0.01 | 0.29 (0.12-0.72) | ||
Yes | 3 (8.1) | 272 (28.2) | ||
No | 34 (91.9) | 694 (71.8) | ||
Extrahepatic | < 0.01 | 2.55 (1.77-3.67) | ||
Yes | 16 (43.2) | 164 (17.0) | ||
No | 21 (56.8) | 802 (83.0) |
Table 4 Synchronous and metachronous metastasis in inactive carriers and control group n (%)
Metastatic sites | IC group (n = 108) | Control group (n = 966) | P value | HR (95% CI) |
Liver | < 0.01 | 0.36 (0.22-0.59) | ||
Yes | 11 (10.2) | 272 (28.2) | ||
No | 97 (89.8) | 694 (71.8) | ||
Extrahepatic | < 0.01 | 2.24 (1.66-3.01) | ||
Yes | 41 (38.0) | 164 (17.0) | ||
No | 67 (62.0) | 802 (83.0) |
Table 5 Synchronous and metachronous metastasis in resolved hepatitis B and control groups n (%)
Metastatic sites | RHB group (n = 187) | Control group (n = 966) | P value | HR (95% CI) |
Liver | < 0.01 | 0.63 (0.46-0.85) | ||
Yes | 33 (17.6) | 272 (28.2) | ||
No | 154 (82.4) | 694 (71.8) | ||
Extrahepatic | < 0.01 | 1.54 (1.16-2.04) | ||
Yes | 49 (26.2) | 164 (17.0) | ||
No | 138 (73.8) | 802 (83.0) |
Table 6 Clinical features of liver metastatic lesions in two groups n (%)
Metastatic lesion | Study group | Control group | P value |
Number | 47 | 272 | < 0.05 |
Single | 17 (36.2) | 73 (26.8) | |
Multiple | 30 (63.8) | 199 (74.2) | |
Size (cm) | 3.6 ± 2.0 | 3.9 ± 1.3 | NS |
Resected | 14 (29.8) | 43 (15.8) | < 0.05 |
- Citation: Qiu HB, Zhang LY, Zeng ZL, Wang ZQ, Luo HY, Keshari RP, Zhou ZW, Xu RH. HBV infection decreases risk of liver metastasis in patients with colorectal cancer: A cohort study. World J Gastroenterol 2011; 17(6): 804-808
- URL: https://www.wjgnet.com/1007-9327/full/v17/i6/804.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i6.804